Renaissance Technologies
CRDL

Renaissance Technologies’s Cardiol Therapeutics CRDL Stock Holding History

Renaissance Technologies’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$310K Buy
+229,806
New +$236K ﹤0.01% 2781
2023
Q2 		– Sell
-10,100
Closed -$5K – 3971
2023
Q1 		$5K Buy
+10,100
New +$5.97K ﹤0.01% 3914
2022
Q1 		– Sell
-93,000
Closed -$171K – 4117
2021
Q4 		$171K Sell
93,000
-51,900
-36% -$143K ﹤0.01% 3566
2021
Q3 		$598K Buy
+144,900
New +$525K ﹤0.01% 2812

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies's CRDL Position: Q1 2026 in Review

Renaissance Technologies opened a new position in Cardiol Therapeutics (CRDL) in Q1 2026: 229,806 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #2781 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in CRDL as recently as Q1 2023.

Renaissance Technologies first reported a position in CRDL in Q3 2021 and has held it in 4 quarters since. The position peaked at $598K in Q3 2021. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Renaissance Technologies held 229,806 shares of Cardiol Therapeutics worth $310K as of Q1 2026.
  • Cardiol Therapeutics was a new Renaissance Technologies position in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2781 holding.
  • Renaissance Technologies first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • Renaissance Technologies's Cardiol Therapeutics position peaked at $598K in Q3 2021.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.